All-trans retinoic acid and arsenic combination therapy benefits low-to-intermediate-risk patients with newly diagnosed acute promyelocytic leukaemia: a long-term follow-up based on multivariate analysis.
Zhu H, Hu J, Li X, Chen L, Zhao H, Zhou W, Wang L, Zhao X, Zhang Y, Chen Y, Sun H, Chen Q, Chen Y, Zhao W, Mi J, Shen Z, Chen Z, Wang Z, Li J, Chen S.
Zhu H, et al. Among authors: chen z, chen l, chen q, chen s, chen y.
Br J Haematol. 2015 Oct;171(2):277-280. doi: 10.1111/bjh.13375. Epub 2015 Mar 30.
Br J Haematol. 2015.
PMID: 25824580
Free article.
No abstract available.